MB
IOVA icon

MPM BioImpact’s Iovance Biotherapeutics IOVA Stock Holding History

MPM BioImpact’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,708,582
Closed -$9.02M – 47
2025
Q1 		$9.02M Buy
2,708,582
+34,677
+1% +$179K 1.55% 29
2024
Q4 		$19.8M Buy
2,673,905
+267,191
+11% +$2.48M 2.81% 11
2024
Q3 		$22.6M Buy
2,406,714
+40,000
+2% +$379K 3.39% 7
2024
Q2 		$19M Buy
2,366,714
+166,714
+8% +$1.79M 2.95% 7
2024
Q1 		$32.6M Sell
2,200,000
-1,089,470
-33% -$12.7M 5.24% 3
2023
Q4 		$26.7M Buy
3,289,470
+2,073
+0.1% +$10.8K 6.26% 2
2023
Q3 		$15M Buy
3,287,397
+337,279
+11% +$2.2M 3.99% 8
2023
Q2 		$20.8M Buy
2,950,118
+335,141
+13% +$2.4M 4.18% 8
2023
Q1 		$16M Buy
2,614,977
+465,427
+22% +$3.21M 4.15% 11
2022
Q4 		$13.7M Buy
2,149,550
+449,550
+26% +$3.51M 3.56% 11
2022
Q3 		$16.3M Buy
1,700,000
+500,000
+42% +$5.77M 3.86% 11
2022
Q2 		$13.2M Buy
+1,200,000
New +$15.7M 3.68% 6

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MPM BioImpact's IOVA Position: Q2 2025 in Review

MPM BioImpact sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 2,708,582 shares — an estimated $9.02M sold.

MPM BioImpact first reported a position in IOVA in Q2 2022 and held it in 12 quarters. The position peaked at $32.6M in Q1 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • MPM BioImpact reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • MPM BioImpact sold 2,708,582 Iovance Biotherapeutics shares in Q2 2025, an estimated $9.02M.
  • MPM BioImpact first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 12 quarters.
  • MPM BioImpact's Iovance Biotherapeutics position peaked at $32.6M in Q1 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on MPM BioImpact's 13F filing for Q2 2025, filed 14 Aug 2025.